Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.
Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.
根據2024年1月11日向美國證券交易委員會（SEC）提交的新通知，在加拿大註冊的生物技術公司Clearmind Medicine Inc. 已成功完成證券的豁免發行，籌集了240萬美元。此次發行持續不超過一年，包括股票、期權、認股權證和其他收購證券的權利。該公司由首席執行官阿迪·祖洛夫-沙尼博士領導，表示所得款項均不會用於向其執行官、董事或發起人付款。Aegis Capital Corp. 參與了這筆交易，獲得的銷售佣金估計爲19.2萬美元。此次發行是根據D條例第506（b）條進行的，該條允許在滿足某些條件的情況下在沒有美國證券交易委員會註冊的情況下出售證券。Clearmind Medicine證實，所有證券均已出售，共有12名投資者參與了此次發行。
根據2024年1月11日向美國證券交易委員會（SEC）提交的新通知，在加拿大註冊的生物技術公司Clearmind Medicine Inc. 已成功完成證券的豁免發行，籌集了240萬美元。此次發行持續不超過一年，包括股票、期權、認股權證和其他收購證券的權利。該公司由首席執行官阿迪·祖洛夫-沙尼博士領導，表示所得款項均不會用於向其執行官、董事或發起人付款。Aegis Capital Corp. 參與了這筆交易，獲得的銷售佣金估計爲19.2萬美元。此次發行是根據D條例第506（b）條進行的，該條允許在滿足某些條件的情況下在沒有美國證券交易委員會註冊的情況下出售證券。Clearmind Medicine證實，所有證券均已出售，共有12名投資者參與了此次發行。
有用
沒用